Prime Medicine, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| PRME | PRQR | DTIL | NTLA | EDIT | SCTX | |
|---|---|---|---|---|---|---|
| Market cap | 901.44M | 198.98M | 226.84M | 1.72B | 417.74M | 317.67M |
| P/E (TTM) | — | — | 32.5 | — | — | — |
| Forward P/E | -5.6 | -3.0 | -4.4 | -4.8 | -3.6 | -4.6 |
| Price/book | 22.1 | 2.2 | 4.4 | 2.4 | 4.0 | -0.3 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +18.90% | −42.44% | +5.29% | −12.60% | +1.12% | −11.54% |
| Today | +9.23% | +2.92% | +16.50% | +3.79% | +4.62% | +3.58% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All PRME news ›Financial Comparison: Prime Medicine (PRME) & Its Peers
Posted by Kim Johansen on Nov 3rd, 2026 Prime Medicine (NASDAQ:PRME – Get Free Report) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Prime Medicine to…
Prime Medicine doses first patient in Wilson disease editing trial
Pam Belluck is a seasoned health and science journalist whose work explores the impact of medicine, policy, and innovation on individuals and society. She has reported extensively on topics like reproductive health, long-term illness,…
Analysts Have Conflicting Sentiments on These Healthcare Companies: Lakefront Biotherapeutics (LKFT), Prime Medicine, Inc. (PRME) and Electrocore (ECOR)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Lakefront Biotherapeutics (LKFT), Prime Medicine, Inc. (PRME) and Electrocore (ECOR). Morgan Stanley analyst Judah Frommer maintained a Hold rating on…
Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease
-- Global, first-in-human study underway designed to evaluate safety, tolerability, and initial clinical efficacy of PM577a -- -- PM577a is designed as a one-time therapy to correct the H1069Q mutation in ATP7B, the most prevalent Wilson…
JPMorgan Initiates Praxis Precision Medicines at Overweight With $700 Price Target
Praxis Precision Medicines has an average rating of buy and mean price target of $650, according to analysts polled by FactSet. ... Praxis Precision Medicines, Inc. Biotechnology & Medical Research JPMorgan Initiates Praxis Precision…
Prime Medicine (NASDAQ:PRME) Stock Jumps 8.5% - Time to Buy?
Prime Medicine, Inc. (NASDAQ:PRME - Get Free Report)'s share price shot up 8.5% on Thursday. The company traded as high as $3.46 and last traded at $3.3950. Approximately 2,000,009 shares traded hands during mid-day trading, a decline of…
Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why
FDA Clearance for PM647 Supports PRME’s Growth Prospects A key positive development for Prime Medicine is the FDA's recent clearance of its investigational new drug application last month for PM647, an investigational gene-editing therapy…
Primech Holdings Ltd. (NASDAQ:PMEC) Stock Short Interest Falls 84.3%
Posted by Sarita Garza on Oct 12th, 2026 Separately, Weiss Ratings downgraded shares of Primech from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, August 14th. One investment analyst has rated the stock with a…
Prime Medicine (PRME) Stock Draws Traders On FDA Trial Wins
Prime Medicine Inc. stocks have been trading up by 8.88 percent amid bullish sentiment on its gene-editing therapy pipeline. PRME has been quietly grinding higher on the chart. Over the last few weeks, Prime Medicine traded mostly between…
PRME Stock Climbs As FDA Greenlights Gene-Editing Trials
Prime Medicine Inc. stocks have been trading up by 8.88 percent amid heightened investor optimism over its gene-editing pipeline. PRME is trading like a classic high-risk, high-reward biotech. Over the last few weeks, Prime Medicine shares…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- themarketsdaily.com2
- marketbeat.com1
- markets.businessinsider.com1
- marketscreener.com1
- stockstotrade.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 8 articles, not a forecast.